ArticleJournal of immunology (Baltimore, Md. : 1950)2011
Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
Article in Journal of immunology (Baltimore, Md. : 1950), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 85 citations in OpenAlex.
- Do Metastatic Cells Arise from PD-L1International journal of molecular sciences · 2026Review
- Research progress of CD80 in the development of immunotherapy drugs.Frontiers in immunology · 2024Review
- Multidimensional outlook on the pathophysiology of cervical cancer invasion and metastasis.Molecular and cellular biochemistry · 2023Review
- Review
- Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80.British journal of cancer · 2023Article
- Article
- A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity.Bioengineering & translational medicine · 2023Article
- Study of the clinicopathological features of soluble PD-L1 in lung cancer patients.Journal of rural medicine : JRM · 2023Article
- Immune cellular components and signaling pathways in the tumor microenvironment.Seminars in cancer biology · 2022Review
- Review
- The Impact of Different Cell Culture Mediums on CD8+ T Cells Expansion: A Bioinformatics Study.Cell journal · 2022Article
- GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.International journal of molecular sciences · 2022Article
- Dysregulation of B7 family and its association with tumor microenvironment in uveal melanoma.Frontiers in immunology · 2022Article
- Divergent roles of PD-L1 in immune regulation during ischemia-reperfusion injury.Frontiers in immunology · 2022Review
- Expression ofCell journal · 2021Article
- Targeting the DNA damage response in immuno-oncology: developments and opportunities.Nature reviews. Cancer · 2021Review
- The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- The PD-1 Interactome.Advanced biology · 2021Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Programmed death ligand 1 (PDL1, or B7-H1) is expressed constitutively or is induced by IFN-γ on the cell surface of most human cancer cells and acts as a "molecular shield" by protecting tumor cells from T cell-mediated destruction. Using seven cell lines representing four histologically distinct solid tumors (lung adenocarcinoma, mammary carcinoma, cutaneous melanoma, and uveal melanoma), we demonstrate that transfection of human tumor cells with the gene encoding the costimulatory molecule CD80 prevents PDL1-mediated immune suppression by tumor cells and restores T cell activation. Mechanistically, CD80 mediates its effects through its extracellular domain, which blocks the cell surface expression of PDL1 but does not prevent intracellular expression of PDL1 protein. These studies demonstrate a new role for CD80 in facilitating antitumor immunity and suggest new therapeutic avenues for preventing tumor cell PDL1-induced immune suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.